Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 Mg/g in Chinese Adults and Adolescents (12-17 Years of Age) with Moderate to Severe Chronic Hand Eczema

Next Previous
Trial Profile

A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 Mg/g in Chinese Adults and Adolescents (12-17 Years of Age) with Moderate to Severe Chronic Hand Eczema

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Eczema
  • Focus Registrational; Therapeutic Use
  • Acronyms DELTA China
  • Sponsors LEO Pharma

Most Recent Events

  • 27 Feb 2025 According to Leo Pharma media release, The open-label treatment period of the DELTA China trial runs from Week 16 to Week 52 and is still ongoing.Detailed results from this study are planned to submit for scientific presentation and publication at a later date.
  • 27 Feb 2025 Primary endpoint (Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16) has been met,as per results presented in LEO Pharma media release.
  • 27 Feb 2025 Positive Results(Week 0 to Week 16), published in the LEO Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top